Novogenia AG, a Munich-based healthcare company specializing in human genetics and personalized products, has announced its exclusive role as technology and manufacturing partner in a planned clinical study under the 10XREVIV initiative in Abu Dhabi, United Arab Emirates. The study, initially designed for 500 participants, will investigate whether individually tailored nutritional support can improve outcomes for people receiving GLP-1 therapy, a class of medications increasingly used for weight management.
Under the agreement, Novogenia will conduct and evaluate participants’ DNA analyses and, based on those results, develop and manufacture personalized dietary supplements. The study is part of a previously announced collaboration involving healthcare partners M42, 10X Health, and REVIV Global. A contract research organization belonging to M42, Insights Research Organization and Solutions (IROS), along with 10XREVIV, will run the trial.
“The 10XREVIV initiative is a key component of our international growth strategy,” said Dr. Daniel Wallerstorfer, CEO of Novogenia AG. “Through our participation in the planned study, we are contributing our core competencies in genetic analysis and the manufacture of personalized dietary supplements to a scientific study.” He added that the study aims to provide insights into the additional benefits that individually tailored nutritional support can offer to people receiving GLP-1 therapy.
The study’s focus includes determining the extent to which personalized nutritional support, alongside standard care, can positively influence participants’ nutritional status, muscle and fat percentages, well-being—particularly quality of life and fatigue levels—and adherence to treatment. This matters because GLP-1 therapies are becoming more widespread, and ensuring adequate nutrient intake during treatment is gaining importance. A U.S. study published in 2025 involving more than 460,000 adults prescribed GLP-1 therapy found that 22.4% experienced a nutrient deficiency or related complication for the first time within one year, according to the announcement.
The operational launch coincides with strong growth in the global GLP-1 receptor agonist market, which is projected to rise from approximately $66 billion in 2025 to more than $185 billion by 2033, according to market forecasts. That growth creates new opportunities for Novogenia to apply its expertise in genetic analysis and personalized supplement manufacturing to innovative care models, the company said.
For the Middle East, Novogenia has already adapted its products to regional requirements and obtained Halal certification. The company said the initiative strengthens its position as a technology and manufacturing partner in personalized healthcare and supports its broader international expansion. The full announcement was distributed via NEWMEDIAWIRE and is available in the original release.
